- Home
- GRRR vs MREO Comparison
GRRR vs MREO Comparison
Compare GRRR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRRR | MREO |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.4M | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GRRR | MREO |
|---|---|---|
| Price | $14.11 | $0.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $18.00 | $3.90 |
| AVG Volume (30 Days) | 876.9K | ★ 37.3M |
| Earning Date | 11-17-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,747,682.00 | $500,000.00 |
| Revenue This Year | $36.15 | N/A |
| Revenue Next Year | $68.68 | $6,363.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.86 | N/A |
| 52 Week Low | $10.85 | $0.20 |
| 52 Week High | $44.15 | $3.26 |
Technical Indicators
Market Signals| Indicator | GRRR | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 59.56 | 35.45 |
| Support Level | $11.90 | $0.51 |
| Resistance Level | $13.20 | $0.78 |
| Average True Range (ATR) | 0.80 | 0.10 |
| MACD | 0.28 | 0.02 |
| Stochastic Oscillator | 92.41 | 75.34 |
Price Performance
Historical ComparisonAbout GRRR Gorilla Technology Group Inc.
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).